MXPA02012256A - Proteinas v de morbillivirus modificados. - Google Patents

Proteinas v de morbillivirus modificados.

Info

Publication number
MXPA02012256A
MXPA02012256A MXPA02012256A MXPA02012256A MXPA02012256A MX PA02012256 A MXPA02012256 A MX PA02012256A MX PA02012256 A MXPA02012256 A MX PA02012256A MX PA02012256 A MXPA02012256 A MX PA02012256A MX PA02012256 A MXPA02012256 A MX PA02012256A
Authority
MX
Mexico
Prior art keywords
modified
morbillivirus
morbilliviruses
amino acids
mutated
Prior art date
Application number
MXPA02012256A
Other languages
English (en)
Inventor
Christopher L Parks
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of MXPA02012256A publication Critical patent/MXPA02012256A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18461—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)

Abstract

La presente invencion se refiere a Morbillivirus modificados que tienen al menos una mutacion en la region correspondiente a los aminoacidos 112-134 de la proteina V del virus de sarampion, en donde uno o ambos de los aminoacidos 113 o 114 esta mutado. Tales Morbillivirus modificados exhiben una represion reducida de la expresion del gen. Las mutaciones o supresiones adicionales en otras regiones del genoma pueden ser incluidas, incluyendo en la region carboxi-terminal.
MXPA02012256A 2000-06-23 2001-06-21 Proteinas v de morbillivirus modificados. MXPA02012256A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21365500P 2000-06-23 2000-06-23
PCT/US2001/019806 WO2002000694A2 (en) 2000-06-23 2001-06-21 Modified morbillivirus v proteins

Publications (1)

Publication Number Publication Date
MXPA02012256A true MXPA02012256A (es) 2003-04-25

Family

ID=22795965

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012256A MXPA02012256A (es) 2000-06-23 2001-06-21 Proteinas v de morbillivirus modificados.

Country Status (17)

Country Link
US (1) US6664066B2 (es)
EP (1) EP1292615B1 (es)
JP (1) JP2004513616A (es)
KR (1) KR100885325B1 (es)
CN (1) CN1298738C (es)
AT (1) ATE343589T1 (es)
AU (2) AU2001267014B2 (es)
BR (1) BR0111827A (es)
CA (1) CA2409432C (es)
CY (1) CY1105842T1 (es)
DE (1) DE60124098T2 (es)
DK (1) DK1292615T3 (es)
ES (1) ES2273852T3 (es)
IL (1) IL153004A0 (es)
MX (1) MXPA02012256A (es)
PT (1) PT1292615E (es)
WO (1) WO2002000694A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2830887C (en) 2001-06-05 2016-11-29 Curevac Gmbh Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
KR100999316B1 (ko) 2003-06-09 2010-12-10 와이어쓰 엘엘씨 ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의회수를 위한 개선된 방법
DE102004042546A1 (de) * 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
WO2008014979A2 (en) 2006-07-31 2008-02-07 Curevac Gmbh NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
WO2009012155A2 (en) * 2007-07-13 2009-01-22 Medimmune, Llc Preparation of negative-stranded rna viruses by electroporation
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
KR101483715B1 (ko) 2008-01-31 2015-01-19 큐어백 게엠바하 면역증강제／애주번트인 화학식（ＮｕＧｌＸｍＧｎＮｖ）ａ를 포함하는 핵산 및 이의 유도체
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
CA2801523C (en) 2010-07-30 2021-08-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA3162352A1 (en) 2010-10-01 2012-04-05 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
WO2013107290A1 (en) * 2012-01-20 2013-07-25 The Government of the Hong Kong Special Administrative Region of the People's Republic of China A novel paramyxovirus and uses thereof
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243946A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2915728A1 (en) 2013-08-21 2015-02-26 Thomas Kramps Respiratory syncytial virus (rsv) vaccine
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US9552559B2 (en) 2014-05-06 2017-01-24 Elwha Llc System and methods for verifying that one or more directives that direct transport of a second end user does not conflict with one or more obligations to transport a first end user
US10458801B2 (en) 2014-05-06 2019-10-29 Uber Technologies, Inc. Systems and methods for travel planning that calls for at least one transportation vehicle unit
CA2955124C (en) 2014-07-18 2024-01-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Peptides including a binding domain of the viral phosphoprotein (p) subunit to the viral rna free nucleoprotein (n0)
WO2016029168A1 (en) 2014-08-21 2016-02-25 Uber Technologies, Inc. Arranging a transport service for a user based on the estimated time of arrival of the user
US10685416B2 (en) 2015-12-10 2020-06-16 Uber Technologies, Inc. Suggested pickup location for ride services
US10731998B2 (en) 2017-11-05 2020-08-04 Uber Technologies, Inc. Network computer system to arrange pooled transport services

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1394259A3 (en) 1994-07-18 2004-04-14 Karl-Klaus Prof. Dr. Conzelmann Recombinant infectious non-segmented negative strand RNA virus
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
CN1232504A (zh) * 1996-09-27 1999-10-20 美国氰胺公司 在单链负义病毒目病毒内引起减毒的3'基因组启动子区和聚合酶基因中的突变
KR100702523B1 (ko) 1997-05-23 2007-04-04 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클로닝된 뉴클레오타이드 서열로부터 약독화된파라인플루엔자 바이러스를 제조하는 방법
CN1600852A (zh) 1998-03-26 2005-03-30 惠氏控股有限公司 引起麻疹病毒或人呼吸道合胞病毒亚组b减毒的突变

Also Published As

Publication number Publication date
WO2002000694A3 (en) 2002-10-10
US20030206925A1 (en) 2003-11-06
US6664066B2 (en) 2003-12-16
ATE343589T1 (de) 2006-11-15
DE60124098D1 (de) 2006-12-07
CA2409432A1 (en) 2002-01-03
CA2409432C (en) 2010-08-03
IL153004A0 (en) 2003-06-24
KR20030032971A (ko) 2003-04-26
EP1292615B1 (en) 2006-10-25
DK1292615T3 (da) 2007-02-19
AU2001267014B2 (en) 2007-03-15
DE60124098T2 (de) 2007-04-05
CY1105842T1 (el) 2011-02-02
KR100885325B1 (ko) 2009-02-25
CN1437613A (zh) 2003-08-20
BR0111827A (pt) 2003-05-20
EP1292615A2 (en) 2003-03-19
ES2273852T3 (es) 2007-05-16
CN1298738C (zh) 2007-02-07
JP2004513616A (ja) 2004-05-13
PT1292615E (pt) 2007-01-31
AU6701401A (en) 2002-01-08
WO2002000694A2 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
MXPA02012256A (es) Proteinas v de morbillivirus modificados.
ATE321867T1 (de) Zusammensetzungen und methoden zur verwendung von dna polymerasen
EP1322307A4 (en) METHODS OF TREATING CELL PROLIFERATION DISORDERS AND VIRAL INFECTIONS
MXPA00010722A (es) Antigenos de neisseria meningitidis y composiciones que los contienen.
ATE79138T1 (de) Typenspezifische papillomavirus-dns-sequenzen und peptide.
ATE237312T1 (de) In liposomen verkapselte nukleinsäurekomplexe
AU691374B2 (en) 5' to 3' exonuclease mutations of thermostable DNA polymerases
BR9914374A (pt) Sequências genÈmicas de neisseria e métodos para seu uso
ATE185572T1 (de) Kombinatorische pna-bibliotheken und verbesserte syntheseverfahren
ATE361365T1 (de) Streptococcus pneumoniae proteine und nukleinsäuren
DE69941701D1 (de) Mutanten von flt3-l und ihre verwendungen
TR200001709T2 (tr) Yeni neisseria meningitids yüzey proteini
DE60110564D1 (en) Rna polymerase mutanten mit erhöhter thermostabilität
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
CA2495529A1 (en) Noonan syndrome gene
EP1064296A4 (en) THERMOSTABLE DNA POLYMERASE FROM THERMOANAEROBACTER THERMOHYDROSULFURICUS
DE69736801D1 (de) Gereinigte proteine, rekombinante dns-sequenzen und prozesse für die produktion von koffeinfreien getränken
CA2342072A1 (en) Kunitz domain polypeptide zkun6
ATE325874T1 (de) Cd154 varianten und deren verwendung
MXPA01009335A (es) Proteinas recombinantes de adhesiva de haemophilus influenzae.
ATE373095T1 (de) Mutierte muskelspezifische enhancer
WO2003100075A3 (en) Bsnd nucleic acids and proteins
WO2002079459A3 (en) Means for inhibiting proteolytical processing of parkin
Marusich et al. Nucleotide and deduced amino acid sequences of bacteriophage T4 gene 22.
NO971359L (no) Humant galaktokinase-gen

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration